Vectibix (panitumumab) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies